Skip to main content
SpringerLink
Log in

Die Chemotherapie des malignen Melanoms

  • Chapter
Probleme der Erythrozytopoese, Granulozytopoese und des Malignen Melanoms

Part of the book series: Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 21))

  • 22 Accesses

Zusammenfassung

Das maligne Melanom ist ein bösartiger Tumor, der in der Regel vor unseren Augen entsteht, rezidiviert und sich schließlich generalisiert ausbreitet. Der natürliche Verlauf dieser Erkrankung ist außerordentlich variabel. Darin spiegelt sich der Einfluß einer Vielzahl von prognostisch relevanten Faktoren, die wir heute zum Teil kennen. Von besonderem Interesse ist die Tatsache, daß immunologische Faktoren im natürlichen Verlauf dieses Tumors eine wichtige Rolle spielen. Dabei erscheint es verwunderlich, daß auch heute noch eine Immuntherapie dieses Tumors nicht sicher vorhersehbar gelingt. Im Gegensatz zu vielen anderen malignen Tumoren sind die Ergebnisse der Chemotherapie im Stadium der Metastasierung bisher trotz intensiver Bemühungen enttäuschend geblieben.

Auf Einladung gehaltenes Referat Hämatologenkongreß Freiburg 1976

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahmann, D. L.: Nitrosureas in the management of disseminated malignant melanoma. Cancer Treatm. Rep. 60, 747–751 (1976)

    CAS  Google Scholar 

  2. Bonadonna, G.: Treatment of residual neoplastic disease in solid tumours. Biomedicine 24, 141–143 (1976)

    PubMed  CAS  Google Scholar 

  3. Bono, V. H., jr.: Studies on the mechanism of action of DTIC (NSC-45388). Cancer Treatm. Rep. 60, 141–148 (1976)

    CAS  Google Scholar 

  4. Bruckner, H. W., Mokyr, M. B., Mitchell, M. S.: Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-l-triazeno) on immunity in patients with malignant melanoma. Cancer Res. 34, 181–183 (1974)

    PubMed  CAS  Google Scholar 

  5. Burke, P. J., McCarthy, W. H., Milton, G. W.: Imidazole carboxamide therapy in advanced malignant melanoma. Cancer (Philad.) 27, 744–750 (1971)

    Article  CAS  Google Scholar 

  6. Carbone, P. P., Costello, W.: Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treatm. Rep. 60, 193–198 (1976)

    CAS  Google Scholar 

  7. Comis, R. L.: DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treatm. Rep. 60, 165–176 (1976)

    CAS  Google Scholar 

  8. Costanza, M. E., Nathanson, L., Lenhard, R., Wolter, J., Colsky, J., Oberfield, R. A., Schilling, A.: Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea. Cancer (Philad.) 30, 1457–1461 (1971)

    Article  Google Scholar 

  9. Cowan, D. H., Bergsagel, D. E.: Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide (NSC-45388). Cancer Chemother. Rep. 55, 175–181 (1971)

    PubMed  CAS  Google Scholar 

  10. Currie, G. A., McElwain, T. J.: Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma; a pilot study. Brit. J. Cancer 31, 143–156 (1975)

    Article  PubMed  CAS  Google Scholar 

  11. DeVita, V. T., jr., Fisher, R. I.: Natural history of malignant melanoma as related to therapy. Cancer Treatm. Rep. 60, 153–157 (1976)

    Google Scholar 

  12. Eilber, F. R., Morton, D. L., Holmes, E. C., Parks, F. C., Ramming, K. P.: Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. New Engl. J. Med. 294, 237–240 (1976)

    Article  PubMed  CAS  Google Scholar 

  13. Gerner, R. E., Moore, G. E.: Study of 5-(3,3-dimethyl-l-triazeno)imidazole-4-earboxamide (NSC-45388) in patients with disseminated melanoma. Cancer Chemother. Rep. 57, 83–84 (1973)

    PubMed  CAS  Google Scholar 

  14. Gottlieb, J. A., Serpick, A. A.: Clinical evaluation of 5-(3,3-dimethyl-l-triazeno)imidazole-4- carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules. Oncology 25, 225–233 (1971)

    Article  PubMed  CAS  Google Scholar 

  15. Gutterman, J. U., Mavligit, G. M., Gottlieb, J. A., Burgess, M. A., McBride, C. E., Einhorn, L. H., Freireich, E. J., Hersh, E. M.: Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide (DTIC) and bacillus Calmette-Guerin (BCG). Behring Inst. Mitt. No. 56, 235–250 (1975)

    Google Scholar 

  16. Gutterman, J. U., Mavligit, G. M., Reed, R., Burgess, M. A., Gottlieb, J. A., Hersh, E. M.: Bacillus Calmette-Guerin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Cancer Treatm. Rep. 60, 177–182 (1976)

    CAS  Google Scholar 

  17. Ikonopisov, R. L.: The use of BCG in the combined treatment of malignant melanoma. Behring Inst. Mitt. No. 56, 206 - 214 (1975)

    Google Scholar 

  18. Johnson, R. O., Metter, G., Wilson, W., Hill, G., Krementz, E.: Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. Cancer Treatm. Rep. 60, 183–187 (1976)

    CAS  Google Scholar 

  19. Loo, T. L., Housholder, G. E., Gerulath, A. H., Saunders, P. H., Farquhar, D.: Mechanism of action and pharmacology studies with DTIC (NSC-45388). Cancer Treatm. Rep. 60, 149–152 (1976)

    CAS  Google Scholar 

  20. Luce, J. K.: Chemotherapy of malignant melanoma. Cancer (Philad.) 30, 1604–1615 (1972)

    Article  CAS  Google Scholar 

  21. McGovern, V. J.: The classification of melanoma and its relationship with prognosis. Pathology 2, 85–98 (1970)

    Article  PubMed  CAS  Google Scholar 

  22. McKelvey, E. M., Luce, J. K., Talley, R. W., Hersh, E. M., Hewlett, J. S., Moon, T. E.: Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma. Cancer (Philad.) 39, 1–4 (1977)

    Article  CAS  Google Scholar 

  23. McKelvey, E. M., Luce, J. K., Vaitkevicius, V. K., Talley, R. W., Bodey, G. P., Lane, M., Moon, T. E.: Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer (Philad.) 39, 5–10 (1977)

    Article  CAS  Google Scholar 

  24. Montgomery, J. A.: Experimental studies at Southern Research Institute with DTIC (NSC-45388). Cancer Treatm. Rep. 60, 125–134 (1976)

    CAS  Google Scholar 

  25. Moon, J. H.: Combination chemotherapy of malignant melanoma. Cancer (Philad.) 26, 468–473 (1970)

    Article  CAS  Google Scholar 

  26. Moon, J. H., Gailani, S., Cooper, M. R., Hayes, D. M., Rege, V. B., Blom, J., Falkson, G., Maurice, P., Brunner, K., Glidewell, O., Holland, J. F.: Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer (Philad.) 35, 368–371 (1975)

    Article  CAS  Google Scholar 

  27. Nathanson, L., Wolter, J., Horton, J., Colsky, J., Shnider, B. I., Schilling, A.: Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma. Clin. Pharmacol. Ther. 12, 955–962 (1971)

    PubMed  CAS  Google Scholar 

  28. van der Merwe, A. M., Falkson, G., van Eden, E. B., et al.: Metastatic malignant melanoma; imidazole carboxamide in its treatment. Med. Proc. 17, 399–405 (1971)

    Google Scholar 

  29. Vogel, C. L., Comis, R. L., Ziegler, J. L., Kiryabwire, J. W. M.: Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda. Cancer Chemother. Rep. 55, 143–149 (1971)

    PubMed  CAS  Google Scholar 

  30. Wagner, D. E., Ramirez, G., Weiss, A. J., Hill, G., jr.: Combination phase I—II study of imidazole carboxamide (NSC-45388). Oncology 26, 310–316 (1971)

    Article  Google Scholar 

  31. Wanebo, H. J., Woodruff, J., Fortner, J. G.: Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage). Cancer (Philad.) 35, 666–676 (1975)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik, Klinikum der Stadt Nürnberg, Germany

    W. M. Gallmeier

Authors
  1. W. M. Gallmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinischen Universitäts-Klinik, Hugstetter Str. 55, D-7800, Freiburg, Germany

    Georg-Wilhelm Löhr (Direktor) (Direktor)

  2. Medizinische Universitäts-Klinik, Freiburg, Germany

    Heidwolf Arnold , Rupert Engelhardt  & Walter Möbius ,  & 

  3. Medizinische Abteilung des Städt. Krankehauses, Carinagasse 9, A-6807, Feldkirch, Austria

    Gert Mähr

  4. Medizinische Universitäts-Klinik, A-6020, Innsbruck, Germany

    Franz Schmalzl

  5. Onkologische Ableitung, Medizinischen Universitäts-Klinik, Rämistr. 100, Zürich, Germany

    Christian Sauter

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gallmeier, W.M. (1978). Die Chemotherapie des malignen Melanoms. In: Löhr, GW., et al. Probleme der Erythrozytopoese, Granulozytopoese und des Malignen Melanoms. Hämatologie und Bluttransfusion, vol 21. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66945-3_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-66945-3_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-08744-1

  • Online ISBN: 978-3-642-66945-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation